CDC cuts childhood vaccine recommendations from 17 diseases to 11

The Centers for Disease Control and Prevention cut routine childhood vaccine recommendations from 17 diseases to 11, dropping six that had been broadly recommended for all children: rotavirus, COVID-19, influenza, hepatitis A, hepatitis B and meningococcal disease. The revision marks one of the sharpest federal vaccine-policy shifts in decades and immediately raised questions about how much protection children will still get under the new framework.

On January 5, 2026, Jim O’Neill, acting director of the CDC, signed a decision memorandum accepting recommendations from what the agency called a comprehensive scientific assessment of U.S. childhood immunization practices. That action followed a directive from President Donald J. Trump, who ordered the Department of Health and Human Services and the CDC to review international best practices from peer developed countries and align U.S. core childhood vaccine recommendations with them if the evidence supported doing so. The White House said Trump had moved to bring U.S. policy in line with countries such as Denmark, which has fewer routine childhood vaccine recommendations.

The CDC says its child and adolescent immunization schedule pages are being revised to reflect the updated recommendations. KFF’s analysis said the changes reduced the number of diseases targeted by routine recommendations from 17 to 11 and the number of routine vaccines from 13 to 7. Supporters cast the overhaul as an attempt to align federal guidance with the practices of other wealthy countries, while public-health and medical groups warned that the change lacked a clear scientific rationale and could weaken defenses against serious infection.

The policy split widened further when the American Academy of Pediatrics issued its own 2026 childhood vaccine schedule, continuing to recommend routine immunizations for 18 diseases. That set up the first major break between the AAP and the CDC schedule in 30 years, a striking sign of how far federal policy had moved from the longstanding pediatric consensus. The practical effect is likely to reach beyond medical charts: parents and clinicians now face a more complicated map of what remains routinely recommended, what is now risk-based, and what may be covered by insurers and public programs.